Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 10 Aug 2026 for Attovia Therapeutics, Inc.. Read the official filing
Filing timeline
BuySalevenBio Global Strategic Fund IV, L.P.
Insider track record
Disclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
venBio Global Strategic Fund IV, L.P.: trading record in brief
This profile gathers the share dealings of venBio Global Strategic Fund IV, L.P. in Attovia Therapeutics, Inc. Altogether 4 filings, all relating to 6 August 2026.
On the market, this insider has only ever bought: 1 purchase, €5.6M in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
On 10 August 2026 came the latest disclosure, an open-market purchase for €5.6M in Attovia Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to venBio Global Strategic Fund IV, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
2,311,870 sharesCommon StockSEC:0000905148-26-003548:0
821,998 sharesCommon StockSEC:0000905148-26-003548:1
665,147 sharesCommon StockSEC:0000905148-26-003548:2
382,352 shares@ US$17.00Common StockSEC:0000905148-26-003548:3
Canonical exit: 4 Nov 2026 (T+90)
4 of 4 declarations
